We compared the TuPro melanoma cohort (n = 98), which received multi-omics–guided selection of adjuvant, standard of care and beyond standard-of-care therapies in patients with advanced melanoma, to a ...
Fulvestrant and elacestrant utilization on prognostic outcome of patients with HR+ve/HER2-ve MBC. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results